Regeneron Gets FDA OK for Extended Eylea HD Dosing

Dow Jones04-03 00:29

By Colin Kellaher

Regeneron Pharmaceuticals has won Food and Drug Administration approval of extended dosing intervals of up to every 20 weeks for its Eylea HD eye drug.

Regeneron on Thursday said the extended dosing covers patients with wet age-related macular degeneration and diabetic macular edema following one year of successful response based on visual and anatomic outcomes.

The Tarrytown, N.Y., biotechnology company said the new dosing regimen allows patients to be treated as infrequently as two to three times a year, further extending the widest range of dosing intervals of any approved injectable anti-vascular endothelial growth factor, or anti-VEGF, therapy.

Eylea HD generated U.S. sales of nearly $1.64 billion last year.

Regeneron, which develops the Eylea franchise with Germany's Bayer, maintains exclusive rights to the products in the U.S., while Bayer has licensed the exclusive marketing rights outside the U.S., where the companies equally split profits from sales.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 02, 2026 12:29 ET (16:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment